European Companies Search Engine
EU funding (€5,996,590): MEFISTO - Meniscal functionalised scaffold to prevent knee Osteoarthritis onset after meniscectomy Hor18 Mar 2019 EU Research and Innovation programme "Horizon"
Overview
Text
MEFISTO - Meniscal functionalised scaffold to prevent knee Osteoarthritis onset after meniscectomy
MEFISTO will develop two novel solutions to treat meniscus loss as a strategy for preventing the onset of an epidemic of post-meniscectomy knee osteoarthritis (OA) in Europe. Morphological profiling will identify the population of patients who, after meniscal resection, are at higher risk of early compartment degeneration, providing a personalized approach for the patient. The two different reconstructive strategies are: i) a controlled vascularized bioactive biodegradable meniscal scaffold, which will regenerate the native meniscus. This strategy will address younger patients with early osteoarthritic changes. ii) a bioactive non-biodegradable meniscal prosthesis, which will act as a mechanical unloading device and a drug delivery system, with the capacity to modulate the inflammatory environment. This strategy will address patients with advanced OA. A socio-economic analysis of the efficacy of existing meniscal substitutes will complete the project. This analysis is of vital importance for the European healthcare system, as it will provide a clear understanding of the costs and benefits of current clinical practice and predict the impact of the two new interventions. The technological innovation lies in the development of biologically active functionalized nanobiomaterials that can interact with the surrounding articular tissues. The biodegradable scaffold will promote revascularization in the peripheral zone, while leaving the inner zone avascular, reflecting the native meniscal tissue and functionalization with drug delivery micro/nanoparticles of the non-biodegradable device will provide modulation of inflammation. The impact is expected to be significant as so many patients have undergone or will undergo meniscectomy. The interventions developed in MEFISTO will prevent these patients from receiving joint-sacrificing procedures such as metal prosthesis whilst reducing the social burden, associated costs and high levels of morbidity resulting from OA.
Funded Companies:
| Company name | Funding amount |
| ACTIVE IMPLANTS (ISRAEL) Ltd. | €0.00 |
| ACTIVE IMPLANTS B.V. | €802,763 |
| AIM GmbH - ASSESSMENT IN MEDICINE RESEARCH AND CONSULTING | €248,125 |
| Consiglio Nazionale Delle Ricerche | €461,875 |
| Etablissement Francais du Sang | €216,875 |
| GEISTLICH BIOMATERIALS VERTRIEBSGESELLSCHAFT mbH | €361,250 |
| GEISTLICH PHARMA AG | €0.00 |
| KLINIKUM DER UNIVERSITAET REGENSBURG | €543,750 |
| Orthokey Italia Srl | €253,125 |
| SCIPROM Sàrl | €320,000 |
| Tissue Click Ltd. | €401,250 |
| Universidad de Santiago de Compostela | €482,198 |
| Universita Humanitas | €847,375 |
| UNIVERSITAIR MEDISCH CENTRUM UTRECHT | €559,443 |
| Universiteit Antwerpen | €498,563 |
Source: https://cordis.europa.eu/project/id/814444
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "ACTIVE IMPLANTS (ISRAEL) Ltd. - EU funding (€5,996,590): MEFISTO - Meniscal functionalised scaffold to prevent knee Osteoarthritis onset after meniscectomy"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
